Extracellular signal-regulated kinase (ERK1/2, gene products MAPK3/MAPK1) is the MAPK cascade's growth channel: growth factors bind receptor tyrosine kinases, RAS recruits RAF, RAF phosphorylates MEK, MEK doubly phosphorylates ERK — and ERK enters the nucleus to phosphorylate the transcription factors (Elk-1, c-Fos, Myc) that start the cell cycle. It is the most-studied kinase route in biology and the axis whose oncogenic overdrive (RAS- or RAF-mutant) drives a large fraction of human cancers and their targeted therapies.
Gene
MAPK3 (ERK1, 16p11.2) and MAPK1 (ERK2, 22q11.22)
Family
Classical MAPKs (CMGC kinases)
Location
Cytoplasm; translocates to nucleus when phosphorylated
Structure
~360 aa Ser/Thr kinase; Thr-Glu-Tyr activation loop
ERK1 and ERK2 are 85% identical, functionally near-redundant kinases with the family's Thr-Glu-Tyr activation motif — MEK's dual phosphorylation is the only physiological on-switch.
A dedicated docking groove (CD/ED sites) binds the D-domains of substrates and of MEK — specificity by handshake, not active-site fit alone.
Phosphorylation also exposes ERK's nuclear-localisation sequence; the phospho-enzyme accumulates in the nucleus within minutes of stimulation.
Function
Proliferation: immediate-early gene induction (FOS, JUN, EGR1) launches G0→G1; ERK signal duration decides proliferation versus differentiation in the same cell.
Downstream kinases: ERK activates RSKs (S6 kinases), MNKs (translation), and MSKs (chromatin) — spreading the signal from transcription to translation.
Feedback: ERK phosphorylates SOS and RAF to dampen its own cascade — adaptation that oncogenic mutations erase.
Regulation
MEK1/2's exclusivity (no other kinase phosphorylates ERK physiologically) makes the MEK-ERK step a clean drug target — trametinib and cobimetinib sit exactly there.
DUSP phosphatases (MKP-1/3) dephosphorylate ERK to close the response; half-lives of phospho-ERK run minutes.
Scaffold KSR assembles RAF-MEK-ERK, and β-arrestin relocalises the cascade to endosomes for sustained signalling from desensitized receptors.
Interactions
Parent cascade RAF-MEK-ERK: see MAPK for the module and its siblings JNK/p38.
With PI3K-AKT it shares RTK inputs; the two pathways' balance sets cell fate, and tumors' drug resistance often reroutes between them.
mTOR integration of ERK-RSK outputs couples growth signals to protein synthesis.
Clinical Relevance
Melanoma: BRAF V600E inhibitors plus MEK inhibitors (dabrafenib/trametinib) — the ERK axis's flagship therapy; ERK inhibitors (ulixertinib) counter the paradoxical reactivation resistance.
Cancer breadth: RAS mutations keep ERK constitutively active in pancreatic, colorectal, and lung cancers — direct RAS inhibitors (sotorasib for KRAS G12C) now attack the cascade's top.
Research marker: phospho-ERK staining is the readout of pathway activation in tumors and the pharmacodynamic marker of RAF/MEK drug trials.